Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Diamyd Medical AB's Revenue for the
three
months ended in May. 2026 was $0.01 Mil. Diamyd Medical AB's average Accounts Receivable for the
three
months ended in May. 2026 was $0.01 Mil.
Hence, Diamyd Medical AB's Receivables Turnover for the
three
months ended in May. 2026 was 1.17.
Diamyd Medical AB (OTCPK:DYMDF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Diamyd Medical AB Receivables Turnover Related Terms
Diamyd Medical AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYMDF vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a Receivables Turnover of 1.17 as of May. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Diamyd Medical AB and its competitors. According to the industry distribution chart, Diamyd Medical AB ranks #206 out of 842 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Diamyd Medical AB's Receivables Turnover too high?
Diamyd Medical AB's current Receivables Turnover is 1.17. The Biotechnology industry median Receivables Turnover is 5.27. Diamyd Medical AB's value of 1.17 is 77.8% below this industry median. Based on the distribution chart, Diamyd Medical AB ranks #206 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #206 out of 842 companies for Receivables Turnover. This places Diamyd Medical AB in the top 25% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Diamyd Medical AB's value of 1.17 is 77.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Receivables Turnover of 1.17 is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Receivables Turnover is 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current Receivables Turnover of 1.17. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current Receivables Turnover is 1.17 and 77.8% below the Biotechnology industry median of 5.27. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current Receivables Turnover is 1.17 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
Receivables Turnover: 1.17
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
Industry Position: 77.8% below the Biotechnology median (#206 of 842)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
